hit counter

Human Substantia Nigra Neurons Tracked Prior Reward and Faster Motivation

MHD featured image for substantia nigra dopamine reward-history signals.

A 2026 iScience study recorded 27 substantia nigra neurons during deep-brain-stimulation surgery in 11 Parkinson’s disease patients and found that prior reward shaped both putative dopamine-neuron firing and the next reaction time: responses were faster after a +$10 outcome than after neutral or negative outcomes (0.916 s vs. 1.017 s, p = 0.0175).1 Research Highlights …

Read more

tVNS Alters Effort and Reward Decisions in Severe Depression

Photoreal illustration of an ear-clip vagus nerve stimulation electrode, with neural pathway motifs representing reward-effort circuits.

An ear-clip that modulates mood by stimulating the vagus nerve has obvious appeal — but the evidence base for non-invasive tVNS in depression has been mixed for a decade. A 2026 cross-over RCT by Forbes et al. sharpens what specifically tVNS does well.1 Research Highlights Transcutaneous vagus nerve stimulation (tVNS) is a non-invasive ear-electrode version …

Read more

Genetic Risk for Low Vitamin D Linked to Lower Social Motivation in First-Episode Psychosis (2024 Study)

Recent research reveals a notable association between vitamin D levels and the severity of negative symptoms in individuals with first-episode psychosis (FEP). A new study explored the genetic predisposition towards lower vitamin D levels and its impact on symptom severity in schizophrenia and related disorders. Highlights: Vitamin D & Psychosis Connection: Lower levels of vitamin …

Read more

Phentermine For ADHD: An Uninvestigated Treatment

Phentermine is an anorectic medication utilized principally for the short-term treatment of obesity as an adjunct to caloric restriction, dietary modifications, and physical exercise.  It is formally classified as a psychostimulant due to the fact that it increases mental and physical arousal [via sympathomimetic mechanisms].  Specifically, phentermine facilitates central and peripheral catecholamine release (primarily of …

Read more

Vyvanse For Depression: Lisdexamfetamine As An Adjunct Treatment

Vyvanse (Lisdexamfetamine) is a drug developed by Shire Pharmaceuticals as a successor to Adderall.  Vyvanse was first approved for the treatment of attention-deficit/hyperactivity disorder  (ADHD) in 2007.  In 2015, Vyvanse was approved for binge eating disorder and was found to successfully minimize appetite and number of binge eating episodes per week compared to a placebo. …

Read more